US23282W6057 - Common Stock
SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four presentations at the...
These two biotech stocks could be big winners in the years ahead.
With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas.
With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation.
SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled...
They'll replace Whirlpool and Zions Bancorp on March 18.
SOUTH SAN FRANCISCO, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 29, 2024 it...
SOUTH SAN FRANCISCO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is joining the European...
Grant Funding Provided by Cytokinetics to Each Organization to Help Increase Clinical Trial Engagement Among Historically Underrepresented Groups...
Cytokinetics reports Q4 financial results with a GAAP EPS miss and revenue decrease.
Topline Results from SEQUOIA-HCM Announced in DecemberShowed Statistically Significant and Clinically Meaningful Increasein Primary Efficacy Endpoint and...
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report...
Cytokinetics (CYTK) experiences volatility as its CEO states the company is not actively undergoing a sales process but remaining receptive to discussions.
These are the biotech stocks to buy that you must have on your watchlist for the coming bull run. It could get started as soon as this month.
Cytokinetics is looking to take on Bristol Myers Squibb in treating a heart disease.
SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President...
Cytokinetics' CFO resignation sparks a 2.2% drop in stock; Truist analyst sees it as a buying opportunity due to personal health reasons cited by CEO.
Total of $100,000 Awarded to Five Patient Advocacy Organizations to Support Communications and Community Outreach...
Investors should consider picking up these healthcare stocks at 52-week lows to benefit from their potential rebound.
New Data Show Treatment with Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy Resulted in Favorable Structural Remodeling, Improvements...
UBS has downgraded Cytokinetics (CYTK) to neutral, commenting that it believes some of the potential M&A premium has already been baked into the stock’s price. Read more here.
SOUTH SAN FRANCISCO, Calif., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced an upcoming presentation at CMR...